Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2025 10:30 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy...
April 21, 2022 13:20 ET | Source: Biofrontera Inc.

Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®

Ameluz® for the treatment of actinic keratoses now at www.ameluz.comXepi® for the treatment of impetigo now at www.xepicream.com WOBURN, Mass. , April 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera...
January 13, 2022 08:45 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today...
December 01, 2021 19:05 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Closing of $15 Million Private Placement

WOBURN, MA., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI; BFRIW) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
November 23, 2021 08:15 ET | Source: Biofrontera Inc.

Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021

WOBURN, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial...